Stem cells are most commonly derived from tissues of healthy adults such as the skin, brain, bone marrow, and nasal mucosa.
Stem cells are being investigated as a possible treatment for glaucoma because they may have the potential to protect the optic nerve from further damage and slow the progression of vision loss due to glaucoma. Stem cells may also have the potential to replace ocular tissues that have degenerated in eyes with glaucoma. These tissues include the trabecular meshwork, which composes the drain of the eye and regulates intraocular pressure, and the optic nerve, which transmits visual information from the eye to the brain. This is an exciting possibility because at this time we have no treatments that can restore vision once it has been lost due to glaucoma.
Several important goals must be accomplished before stem cells can be used to treat glaucoma. Researchers need methods to reliably differentiate stem cells into the specific ocular tissues that are damaged in glaucoma. The stem cells must be safely implanted into the correct site within the eye and, in order to be functional, must establish working connections with specific parts of the brain. Finally, any stem cells implanted into a patient with glaucoma must remain stable for a significant period of time and not cause any serious side effects.
Although important progress is being made towards reaching these goals, stem cell therapy for glaucoma needs to be carefully studied in humans. Despite this fact, several international clinics offer stem cell treatments for a variety of degenerative conditions, including glaucoma. None of these treatments have yet proven to be effective in glaucoma and, in a few cases, have resulted in serious side effects. Patients with glaucoma should only consider receiving stem cell treatment in the context of a well-regulated clinical trial after consultation with their personal ophthalmologist.
There is a great deal of hope and enthusiasm for the role of stem cells in the future treatment of glaucoma that is firmly supported by groundbreaking, strong fundamental basic science research.
Article by Alice L. Williams, MD, Michael Waisbourd, MD, and L. Jay Katz, MD.
Posted on January 9, 2016; Last reviewed on April 19, 2022.
Alice L. Williams, MD
Alice L. Williams, MD is a board-certified ophthalmologist and a glaucoma specialist at Wills Eye Hospital. She has published numerous peer-reviewed manuscripts, several book chapters, and was an editor for the Glaucoma Section in the Seventh Edition of the Wills Eye Manual.
Michael Waisbourd, MD
Dr. Michael Waisbourd, MD is an ophthalmologist in Philadelphia, Pennsylvania. He is affiliated with Thomas Jefferson University Hospitals.
L. Jay Katz, MD
L. Jay Katz, MD is a member of the Wills Eye Glaucoma Service and a Professor of Ophthalmology at Sidney Kimmel Medical College. He has wide-ranging interests in glaucoma, including drug evaluation, the roles of laser and medical management in glaucoma treatment and optic nerve scanning methodologies and has delivered hundreds of lectures, teaching sessions and courses on these topics.
